跳至主要内容
临床试验/NCT02974946
NCT02974946已完成不适用

Kidney Protection Using the RenalGuard® System in Cardiac Surgery

The Royal Wolverhampton Hospitals NHS Trust2 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2017年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
220
试验地点
2
主要终点
Incidence of AKI as defined by the RIFLE criteria

研究概览

简要总结

This is a prospective randomised control trial 1:1 in patients at risk of developing Acute Kidney Injury after cardiac surgery comparing the RenalGuard® System to current medical treatment. 110 patients will be recruited for each group. The aim of the study is to assess whether the RenalGuard® system reduces Acute Kidney Injury (AKI) after cardiac surgery as compared to current practice.

详细描述

Patients undergoing elective or in-house urgent cardiac surgery will be approached for the KIDNEY study if they fulfil the inclusion criteria. Upon consent pre-operative blood tests will be as per the usual practice. Moreover, 2ml of the serum will be stored for NGAL analysis.

Following the consenting process, patients will be randomised (envelop- based) into either having the RenalGuard® System (Study group) or current medical management (Control group).

Study group:

Patients in the study group will have the RenalGuard® System started in anaesthetic room once the peripheral line and arterial lines are sited. The RenalGuard® System will continue to run throughout the cardiac procedure in the operating room and up to 6 hours post-op after the patient has been transferred to the unit. Patients will be managed at a zero balance i.e. volume of the urine output will be matched to the volume of Hartmann's fluid infusion. Forced diuresis is then initiated.

Control group:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing surgery (elective or in-house urgent)
  • Patient 18 years old and over
  • Patient able to give written consent
  • Patient at risk of developing AKI after cardiac surgery (at least one factor)
  • Diabetics (IDDM or NIDDM) with normal kidney function pre-op
  • Patients with eGFR 20-60
  • Patients undergoing combined cardiac procedures when the CPB time is likely to exceed 120 minutes
  • Patients with Hb of 12.5 g/dl or below
  • Logistic Euroscore of 5 and above
  • Patient not involved with another study

排除标准

  • Emergency surgery
  • Patient unable to give written consent
  • Patient already dialysis dependent or eGFR <20
  • Patient partaking in another study
  • Pregnant patients

结局指标

主要结局

Incidence of AKI as defined by the RIFLE criteria

时间窗: 50% rise in pre-op serum creatinine within 3 days of surgery

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验